<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Large granular lymphocyte (LGL) <z:hpo ids='HP_0001909'>leukemia</z:hpo> is characterized by clonal expansion of antigen-activated cytotoxic T cells (CTL) </plain></SENT>
<SENT sid="1" pm="."><plain>Patients frequently exhibit seroreactivity against a human T-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> virus (HTLV) <z:chebi fb="0" ids="53000">epitope</z:chebi>, BA21 </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0001915'>Aplastic anemia</z:hpo>, <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> are <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> diseases that can also be associated with similar aberrant CTL activation (LGL-BMF) </plain></SENT>
<SENT sid="3" pm="."><plain>We identified a BA21 <z:chebi fb="7" ids="16670">peptide</z:chebi> that was specifically reactive with LGL <z:hpo ids='HP_0001909'>leukemia</z:hpo> sera and found significantly elevated antibody reactivity against the same <z:chebi fb="7" ids="16670">peptide</z:chebi> in LGL-BMF sera </plain></SENT>
<SENT sid="4" pm="."><plain>This finding of shared seroreactivity in LGL-BMF conditions and LGL <z:hpo ids='HP_0001909'>leukemia</z:hpo> suggests that these diseases might share a common pathogenesis </plain></SENT>
</text></document>